

**REMARKS**

Entry of the forgoing and further and favorable consideration of the subject application are respectfully requested. As stated correctly in the Final Office Action, Claims 1-31 are pending of which Claims 11-31 are withdrawn from consideration. The Examiner has allowed Claims 1-4 and 9 and rejected Claims 5-8, and 10.

By this Amendment After Final, Claims 5 and 10 have been amended to recite the elected nucleotide sequence and its encoded polypeptide sequence and to more precisely define the invention. New Claim 32, has been added to recite hybridization. Support for the amendments can be found in the Sequence Listing as well as the originally filed claims. Further support for the amended claims can be found in the Specification on page 8 lines 13-15, page 10 lines 2-5, page 12 lines 21-26 and page 33 lines 20-21. Further support for new claim 32 and amended claim 10 can be found in the Specification on page 21 lines 20-25.

No new matter has been added with this amendment.

Claims 11-31 have been cancelled without prejudice. Applicants reserve the right to file a division and/or continuation on the cancelled subject matter.

CONCLUSION

Reconsideration and withdrawal of the pending rejections are respectfully requested and a Notice of Allowance is earnestly solicited.

If the Examiner feels that a telephone conference would expedite prosecution of this application, he is invited to call the undersigned at 781-398-2300.

Any deficiency or overpayment for this reply should be charged or credited to Deposit Account No. 50-1040. One duplicate copy of this letter is enclosed.

Respectfully submitted,

GENOME THERAPEUTICS CORPORATION

By 

Robert L. Spadafora, Jr.

Registration No 46,197

Telephone (781) 398-2300

Facsimile (781) 398-2530

Waltham, Massachusetts 02453

Dated:

6/24/03